Ironwood Pharmaceuticals, Inc. (FRA:I76)

Market Cap	546.80M +68.7%
Revenue (ttm)	288.92M -10.4%
Net Income	24.33M
EPS	0.15
Shares Out	n/a
PE Ratio	22.47
Forward PE	4.92
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	15
Open	3.840
Previous Close	3.720
Day's Range	3.660 - 3.840
52-Week Range	0.478 - 4.480
Beta	n/a
RSI	49.03
Earnings Date	Feb 13, 2026

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-...

• Industry: Pharmaceutical Preparations
• Founded: 1998
• Employees: 253
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: I76

Financial Performance

Financial numbers in USD